CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 5, 2024 4:01 PM EDT-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 20 patients have had cells collected across all regions as of mid-July-
-Clinical trials ongoing for next generation CAR T product candidates, CTX112 and CTX131 targeting CD19 and CD70 respectively, across multiple indications-
-Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) and for CTX131 in hematological malignancies-
-Clinical trials ongoing for in vivo gene editing product candidates, CTX310 and CTX320 targeting ANGPTL3 and LPA, respectively-
-Clinical... More
